Structural Adaptation of Darunavir Analogs Against Primary Mutations in HIV-1 Protease

HIV-1 protease is one of the prime targets of agents used in antiretroviral therapy against HIV. However, under selective pressure of protease inhibitors, primary mutations at the active site weaken inhibitor binding to confer resistance. Darunavir (DRV) is the most potent HIV-1 protease inhibitor i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ACS Infect Dis
Glavni autori: Lockbaum, Gordon J., Leidner, Florian, Rusere, Linah N., Henes, Mina, Kosovrasti, Klajdi, Nachum, Gily S., Nalivaika, Ellen A., Bolon, Daniel N.A., Ali, Akbar, Yilmaz, Nese Kurt, Schiffer, Celia A.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6941150/
https://ncbi.nlm.nih.gov/pubmed/30543749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsinfecdis.8b00336
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items